JP6786499B2 - 膵癌のバイオマーカー - Google Patents

膵癌のバイオマーカー Download PDF

Info

Publication number
JP6786499B2
JP6786499B2 JP2017541693A JP2017541693A JP6786499B2 JP 6786499 B2 JP6786499 B2 JP 6786499B2 JP 2017541693 A JP2017541693 A JP 2017541693A JP 2017541693 A JP2017541693 A JP 2017541693A JP 6786499 B2 JP6786499 B2 JP 6786499B2
Authority
JP
Japan
Prior art keywords
protein
pdac
concentration
proteins
reg1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017541693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504609A5 (enExample
JP2018504609A (ja
Inventor
タジャーナ ツルノゴラッツ‐ジャスビック
タジャーナ ツルノゴラッツ‐ジャスビック
トマシュ ラドン
トマシュ ラドン
Original Assignee
クイーン メアリー ユニバーシティ オブ ロンドン
クイーン メアリー ユニバーシティ オブ ロンドン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クイーン メアリー ユニバーシティ オブ ロンドン, クイーン メアリー ユニバーシティ オブ ロンドン filed Critical クイーン メアリー ユニバーシティ オブ ロンドン
Publication of JP2018504609A publication Critical patent/JP2018504609A/ja
Publication of JP2018504609A5 publication Critical patent/JP2018504609A5/ja
Application granted granted Critical
Publication of JP6786499B2 publication Critical patent/JP6786499B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2017541693A 2015-02-05 2016-02-05 膵癌のバイオマーカー Active JP6786499B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1501930.0A GB201501930D0 (en) 2015-02-05 2015-02-05 Biomarkers for pancreatic cancer
GB1501930.0 2015-02-05
PCT/GB2016/050277 WO2016124947A1 (en) 2015-02-05 2016-02-05 Biomarkers for pancreatic cancer

Publications (3)

Publication Number Publication Date
JP2018504609A JP2018504609A (ja) 2018-02-15
JP2018504609A5 JP2018504609A5 (enExample) 2019-03-14
JP6786499B2 true JP6786499B2 (ja) 2020-11-18

Family

ID=52746188

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017541693A Active JP6786499B2 (ja) 2015-02-05 2016-02-05 膵癌のバイオマーカー

Country Status (15)

Country Link
US (3) US10782301B2 (enExample)
EP (2) EP3254111A1 (enExample)
JP (1) JP6786499B2 (enExample)
KR (1) KR102569984B1 (enExample)
CN (1) CN107533062B (enExample)
AU (1) AU2016214140B2 (enExample)
BR (1) BR112017016808A2 (enExample)
CA (1) CA2974775C (enExample)
CL (1) CL2017001972A1 (enExample)
GB (1) GB201501930D0 (enExample)
HK (1) HK1247276A1 (enExample)
IL (1) IL253710B (enExample)
MX (1) MX2017009998A (enExample)
SG (1) SG11201706223VA (enExample)
WO (1) WO2016124947A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11977077B2 (en) 2015-02-05 2024-05-07 Queen Mary University Of London Biomarkers for pancreatic cancer

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008231575A1 (en) 2007-03-27 2008-10-02 Immunovia Ab Protein signature/markers for the detection of adenocarcinoma
GB201517028D0 (en) * 2015-09-25 2015-11-11 Univ London Queen Mary Novel biomarkers for pancreatic cancer
CN107674884A (zh) * 2017-09-05 2018-02-09 上海速创诊断产品有限公司 一种用于检测胰腺癌标记物reg1a的生物素化脂质体及其制备方法和应用
TWI643869B (zh) * 2017-12-14 2018-12-11 國立高雄大學 Molecular extension printing material and preparation method thereof, magnetic molecular extension printing material and preparation method thereof
US20210052231A1 (en) * 2017-12-14 2021-02-25 Salcit Technologies Private Limited Method and system for analyzing risk associated with respiratory sounds
KR102000387B1 (ko) * 2018-02-13 2019-07-15 서울대학교산학협력단 췌관내유두상점액종양의 악성도를 감별할 수 있는 단백질 바이오마커 및 그 용도
CN109358055A (zh) * 2018-12-18 2019-02-19 沈阳理工大学 增敏测定空气中氨的混合指示剂试纸及其制备和检测方法
CN111303281A (zh) * 2019-05-14 2020-06-19 长春恒晓生物科技有限责任公司 制备胰石蛋白抗体及建立检测psp方法
WO2021076036A1 (en) * 2019-10-18 2021-04-22 Reccan Diagnostics Ab Apparatuses and methods for detection of pancreatic cancer
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN117015713A (zh) * 2020-12-22 2023-11-07 伯蒂斯有限公司 用于确定胰腺导管腺癌的亚型的方法及亚型确定试剂盒
WO2022266031A2 (en) * 2021-06-15 2022-12-22 Somalogic Operating Co., Inc. Renal insufficiency prediction and uses thereof
CN113248609B (zh) * 2021-07-14 2021-09-10 深圳市盛波尔生命科学技术有限责任公司 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒
CN115290732B (zh) * 2022-07-14 2025-02-25 西北大学 一种检测胰蛋白酶的电化学生物传感器及其制备方法
WO2026050670A1 (en) * 2024-08-30 2026-03-05 Cedars-Sinai Medical Center Noninvasive test for early detection of pancreatic ductal adenocarcinoma
CN119724622B (zh) * 2024-11-25 2025-12-12 中国人民解放军总医院第五医学中心 一种评价ptt对胰腺癌治疗效果的方法、系统及设备

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
CN1703524B (zh) 2002-09-30 2010-04-07 肿瘤疗法科学股份有限公司 与人胰腺癌相关的基因和多肽
AU2003900747A0 (en) 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20050095611A1 (en) 2003-05-02 2005-05-05 Chan Daniel W. Identification of biomarkers for detecting pancreatic cancer
AU2004239418A1 (en) 2003-05-15 2004-11-25 Europroteome Ag Biomarkers for the differential diagnosis of pancreatitis and pancreatic cancer
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
WO2006081473A2 (en) 2005-01-28 2006-08-03 Children's Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers
ATE555215T1 (de) 2005-06-27 2012-05-15 Wayne John Cancer Inst Molekulare/genetische aberrationen in chirurgischen rändern von pankreaskrebsresektionen stellen eine neoplastische erkrankung dar, die mit dem resultat korreliert
WO2007035684A2 (en) 2005-09-16 2007-03-29 Primera Biosystems, Inc. Method for quantitative detection of short rna molecules
WO2007081680A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
JP2009527735A (ja) 2006-02-17 2009-07-30 チルドレンズ メディカル センター コーポレーション 癌に対するバイオマーカーとしての遊離ｎｇａｌ
US20070231822A1 (en) 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
CA2664383C (en) 2006-09-19 2017-08-22 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
US20080199455A1 (en) * 2006-10-03 2008-08-21 Lobie Peter E Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same
WO2008063479A2 (en) 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
CN101827941B (zh) 2007-04-30 2014-07-16 俄亥俄州立大学研究基金会 用于区分胰腺癌与正常胰腺功能和/或慢性胰腺炎的方法
DK2294215T3 (da) * 2008-05-12 2013-04-22 Genomic Health Inc Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder
WO2009147530A2 (en) * 2008-06-06 2009-12-10 Neuren Pharmaceuticals Ltd Conformation specific antibodies that bind trefoil factors
JP2012100536A (ja) * 2009-03-02 2012-05-31 Genescience Co Ltd 血液試料に含まれる単核球細胞を用いた癌関連遺伝子の発現解析による癌の遺伝子検査方法
IN2012DN05101A (enExample) 2010-01-19 2015-10-23 Immunomedics Inc
EP2415877A3 (en) * 2010-02-17 2012-02-15 Deutsches Krebsforschungszentrum Means and methods for diagnosing pancreatic cancer
WO2011137288A2 (en) 2010-04-30 2011-11-03 The Ohio State University Mirna networks in cancers and leukemias and uses thereof
WO2012100339A1 (en) * 2011-01-27 2012-08-02 University Health Network Methods and compositions for the detection of pancreatic cancer
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
US20140235494A1 (en) * 2011-09-21 2014-08-21 The Universify of North Carolina at Chapel Hill Methods, Kits and Computer Program Products using Hepatocellular Carcinoma (HCC) Biomarkers
DE102012204366B4 (de) 2011-12-16 2017-07-27 Siemens Aktiengesellschaft Verfahren und Kit zur Identifizierung und Quantifizierung von einer einzelsträngigen Ziel-Nukleinsäure
US20150018235A1 (en) * 2012-01-13 2015-01-15 Oncocyte Corporation Methods and Compositions for the Treatment and Diagnosis of Pancreatic Cancer
WO2013107459A2 (en) 2012-01-16 2013-07-25 Herlev Hospital Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
US20130216545A1 (en) * 2012-02-19 2013-08-22 Claresa Levetan Early Diagnosis and Novel Treatment of Cancer
WO2013152989A2 (en) 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer
US20130317083A1 (en) 2012-05-04 2013-11-28 Thomas Jefferson University Non-coding transcripts for determination of cellular states
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US20140271621A1 (en) * 2013-03-14 2014-09-18 Abbott Laboratories Methods of prognosis and diagnosis of pancreatic cancer
US20150018230A1 (en) 2013-06-11 2015-01-15 Indiana University Research And Technology Corp. PLASMA miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
GB201517028D0 (en) 2015-09-25 2015-11-11 Univ London Queen Mary Novel biomarkers for pancreatic cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11977077B2 (en) 2015-02-05 2024-05-07 Queen Mary University Of London Biomarkers for pancreatic cancer

Also Published As

Publication number Publication date
BR112017016808A2 (pt) 2018-04-03
AU2016214140B2 (en) 2021-11-04
CL2017001972A1 (es) 2018-03-23
US11977077B2 (en) 2024-05-07
MX2017009998A (es) 2018-02-01
CN107533062B (zh) 2021-03-23
IL253710A0 (en) 2017-09-28
GB201501930D0 (en) 2015-03-25
US20250251399A1 (en) 2025-08-07
KR102569984B1 (ko) 2023-08-22
CA2974775A1 (en) 2016-08-11
US20220042998A1 (en) 2022-02-10
EP4458849A2 (en) 2024-11-06
KR20170129118A (ko) 2017-11-24
CN107533062A (zh) 2018-01-02
US10782301B2 (en) 2020-09-22
AU2016214140A1 (en) 2017-08-17
US12656346B2 (en) 2026-06-16
EP3254111A1 (en) 2017-12-13
EP4458849A3 (en) 2024-12-04
US20190204323A1 (en) 2019-07-04
IL253710B (en) 2020-08-31
JP2018504609A (ja) 2018-02-15
CA2974775C (en) 2023-11-07
WO2016124947A1 (en) 2016-08-11
SG11201706223VA (en) 2017-08-30
HK1247276A1 (zh) 2018-09-21

Similar Documents

Publication Publication Date Title
US20250251399A1 (en) Biomarkers for pancreatic cancer
WO2021076036A1 (en) Apparatuses and methods for detection of pancreatic cancer
CN104204807B (zh) 用于胃癌的生物标志物及其应用
Chen et al. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia
JP2016538545A (ja) 肝臓癌の診断及び予後判定のための材料及び方法
CN111065925B (zh) Agrin在诊断子宫内膜癌中的应用
KR102087373B1 (ko) 비소세포성 폐암 진단용 단백질 바이오마커 패널 및 이를 이용한 비소세포성 폐암 진단 방법
US20180231559A1 (en) Methods and Compositions for the Diagnosis of Ovarian Cancer
Chen et al. Discovery of novel protein biomarkers in urine for diagnosis of urothelial cancer using iTRAQ proteomics
US20180274037A1 (en) Novel biomarkers for pancreatic diseases
CA3218787A1 (en) Protein biomarkers for non-alcoholic fatty liver disease (nafld)
HK40118234A (en) Biomarkers for pancreatic cancer
KR102128251B1 (ko) 아르기닌이 메틸화된 drd2에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190131

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201028

R150 Certificate of patent or registration of utility model

Ref document number: 6786499

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250